

RESTRICTED BENEFIT CRITERIA - SPIRIVA®

| PROVINCE/PROGRAM | INDICATION | CRITERIA |
|------------------------------|------------|---|
| British Columbia SA | COPD | COPD that failed both Spiriva® Respimat® and Incruse® |
| New Brunswick SA | COPD | Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA or ICS/LABA |
| Newfoundland and Labrador SA | COPD | Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA |
| | ACO | As part of an open triple therapy in patients with an asthma/COPD overlap |
| Nova Scotia EDS | COPD | Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA or ICS/LABA |
| Prince Edward Island SA | COPD | Moderate to severe symptomatic COPD Exacerbating COPD |

ACO: asthma COPD overlap, COPD: chronic obstructive pulmonary disease, EDS: Exception Drug Status, ICS: inhaled corticosteroids, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, SA: Special Authorization, SABA: short-acting beta-agonist